ERBB2 and breast cancer: Although treatment with trastuzumab and other human epidermal growth factor receptor 2 (HER2)-directed therapies are associated with significant efficacy, only patients with the highest levels of HER2 expression, representing approximately 20% of patients with BC, have the potential to respond.